Foresite Capital Management VI LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Foresite Capital Management VI LLC reported 23 stock positions worth $642.6 million. Its top holding was CG Oncology (CGON) at 26.2% of the portfolio, followed by Alumis (ALMS, 18.6%) and Seaport Therapeutics (SPTX, 6.0%). Compared with Q1 2026, it opened 8 new positions, sold out of 2, added to 6 and reduced 1. The biggest buy was a new position in Seaport Therapeutics (SPTX) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $642.6M (Q2 2026)
- SEC Filing
- 0001104659-26-097133 ↗ filed Aug 14, 2026
Holdings Value
Holdings 23 stocks · $642.6M
| CGON CG Oncology Inc. | 26.20% | 2,369,574 | $168.4M | Add +6.7% |
| ALMS Alumis Inc. | 18.60% | 4,247,670 | $119.5M | No change |
| SPTX Seaport Therapeutics Inc. | 6.01% | 1,779,521 | $38.7M | New |
| DNLI Denali Therapeutics Inc. | 5.59% | 1,396,771 | $35.9M | Add +15.4% |
| CLDX Celldex Therapeutics Inc. | 5.09% | 879,713 | $32.7M | Add +178.5% |
| AGIO Agios Pharmaceuticals Inc. | 4.53% | 785,000 | $29.1M | Add +49.5% |
| CRVS Corvus Pharmaceuticals Inc. | 4.26% | 1,831,233 | $27.4M | No change |
| PBLS Parabilis Medicines Inc. | 4.26% | 999,044 | $27.3M | New |
| GHRS GH Research PLC | 3.93% | 940,493 | $25.3M | Add +198.1% |
| JBIO Jade Biosciences Inc. | 3.07% | 886,667 | $19.7M | Add +177.1% |
| HNGE Hinge Health Inc. Class A | 2.85% | 220,400 | $18.3M | No change |
| KYMR Kymera Therapeutics Inc. | 2.61% | 146,332 | $16.8M | No change |
| ATAI Ataibeckley Inc. | 2.26% | 2,750,000 | $14.5M | No change |
| VSTM Verastem Inc. | 1.87% | 3,146,631 | $12.0M | No change |
| BEAM Beam Therapeutics Inc. | 1.76% | 330,000 | $11.3M | New |
| NERV Minerva Neurosciences Inc. | 1.72% | 1,985,584 | $11.0M | Reduce -0.1% |
| AVBP Arrivent Biopharma Inc. | 1.63% | 301,341 | $10.5M | New |
| AURA Aura Biosciences Inc. | 1.47% | 1,333,334 | $9.5M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 1.23% | 212,010 | $7.9M | No change |
| RACC Research Alliance Corp. Class A | 0.50% | 300,000 | $3.2M | New |
| ZURA Zura Bio Ltd. | 0.41% | 450,000 | $2.7M | No change |
| KLRA Kailera Therapeutics Inc. | 0.13% | 37,500 | $826K | New |
| IRON Disc Medicine Inc. | 0.01% | 970 | $71K | New |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
| SPTX Seaport Therapeutics Inc. | New | 6.01% | +6.01 |
| PBLS Parabilis Medicines Inc. | New | 4.26% | +4.26 |
| GHRS GH Research PLC | Add +198.1% | 3.93% | +2.97 |
| CLDX Celldex Therapeutics Inc. | Add +178.5% | 5.09% | +2.92 |
| JBIO Jade Biosciences Inc. | Add +177.1% | 3.07% | +2.09 |
| BEAM Beam Therapeutics Inc. | New | 1.76% | +1.76 |
| AVBP Arrivent Biopharma Inc. | New | 1.63% | +1.63 |
| AURA Aura Biosciences Inc. | New | 1.47% | +1.47 |
| AGIO Agios Pharmaceuticals Inc. | Add +49.5% | 4.53% | +0.67 |
| DNLI Denali Therapeutics Inc. | Add +15.4% | 5.59% | +0.54 |
| RACC Research Alliance Corp. Class A | New | 0.50% | +0.50 |
| KLRA Kailera Therapeutics Inc. | New | 0.13% | +0.13 |
| IRON Disc Medicine Inc. | New | 0.01% | +0.01 |
| CGON CG Oncology Inc. | Add +6.7% | 26.20% | −6.46 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |